GFP Reporter Cell Line - KU-812E

CML is primarily treated with TKIs like Imatinib, which inhibit the Bcr-Abl protein, improving patient survival. Researchers explored alternative strategies for treating CML due to current therapy limitations, notably TKIs. They investigated SMO inhibition within the Hedgehog signaling pathway. Using Cell Line KU-812, they tested SMO-inhibiting compounds, notably MRT92, observing reductions in Gli1 protein levels, increased Gli1 and SMO RNA levels, decreased cell proliferation, and induced apoptosis/autophagy. Additionally, these compounds modulated miRNAs associated with the Hedgehog pathway, suggesting SMO inhibition as a promising therapeutic target for CML, with potential as pathway antagonists.

Figure 1. SMO RNA expression in KU-812 cells was investigated by the researchers. The effects of compounds MRTX, MRT94, MRT92, MRT83, MRTY, and a control compound on SMO RNA expression after 24h (a) or 72h (b) treatment at 10 μM and after 24h (c) or 72h (d) treatment at 50 μM were assessed. (Chiarenza A, et al., 2016)

If your interest lies in studying changes in transcriptional activity, you can utilize the GFP Reporter Cell Line - KU-812E from Creative Biogene to directly monitor GFP reporter gene expression, obviating the need for RT-qPCR and western blot analyses. This approach streamlines the experimental workflow and enables real-time monitoring of transcriptional activity. Furthermore, employing the GFP Reporter Cell Line reduces cellular manipulations, thereby mitigating the risk of cell damage and enhancing the repeatability and reliability of experiments.